

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

**UNITED STATES DISTRICT COURT
WESTERN DISTRICT OF WASHINGTON
SEATTLE DIVISION**

SUSAN FITZL and SAMANTHA HORTON, on
behalf of themselves and a class of all others
similarly situated,

Plaintiffs,

v.

AMAZON.COM, INC.,

Defendant.

Civil Action No. 2:22-cv-00544

**CLASS ACTION COMPLAINT
and DEMAND FOR JURY TRIAL**

Plaintiffs Susan Fitzl and Samantha Horton (collectively, “Plaintiffs”), individually and on behalf of themselves and all others similarly situated, bring this class action lawsuit against Defendant Amazon.com, Inc. (“Amazon” or “Defendant”) based upon personal knowledge as to themselves, the investigation of their counsel, and on information and belief as to all other matters.

INTRODUCTION

1. This is a class action lawsuit against Defendant regarding the manufacture, distribution, and sale of Amazon’s Basic Care-branded “Non-Drowsy” over-the-counter cold and flu medicines that contain Dextromethorphan Hydrobromide (“the “Non-Drowsy Products”).¹

2. The Non-Drowsy Products state prominently on the front of their labels that they are “Non-Drowsy” and “Daytime” products.

¹ The Non-Drowsy Products include: Basic Care Vapor Ice Daytime and Nighttime Severe Cold and Flu Combo Pack, Basic Care Tussin CF Severe, Basic Care Daytime Severe Cold and Flu, Basic Care Cold and Flu Relief Multi-Symptom Daytime/Nighttime Combo Pack Softgels, Basic Care Daytime Cold and Flu, Basic Care Daytime Severe. Plaintiffs reserve the right to amend this list if further investigation and/or discovery reveals that the list should be amended.



3. By prominently labeling the products as “Non-Drowsy” and “Daytime,” Defendant led Plaintiffs and other consumers to believe that the Non-Drowsy Products do not cause drowsiness, and that drowsiness is not a side effect of the products.

4. Defendant also led Plaintiffs and other consumers to believe that the Non-Drowsy Products are for use during the “Daytime” and intended to be used during waking hours.

5. However, one of the active ingredients in the Non-Drowsy Products is Dextromethorphan Hydrobromide (“DM HBr”). While the average consumer may not be aware, drowsiness is a documented side effect of DM HBr at dosages recommended by Defendant in respect to the Non-Drowsy Products. Authorities such as the National Library of Medicine and Mayo Clinic list drowsiness as a side effect of this ingredient.²

6. Plaintiffs and Class members purchased the Non-Drowsy Products with the expectation that the products would not cause drowsiness and that they were intended to be used during waking hours. Because Defendant sold products to consumers that cause drowsiness, Plaintiffs and the Classes were deprived of the benefit of their bargain.

² Dextromethorphan: MedlinePlus Drug Information, National Library of Medicine, <https://medlineplus.gov/druginfo/meds/a682492.html> (last accessed March 23, 2022); Mayo Clinic, *Drugs and Supplements Dextromethorphan (Oral Route)*, <https://www.mayoclinic.org/drugs-supplements/dextromethorphan-oral-route/side-effects/drg-20068661?p=1> (last accessed March 23, 2022).

1 1994 in Bellevue, Washington by Jeff Bezos and is one of the largest retailers in the world. At all
2 relevant times hereto, Defendant was engaged in manufacturing, marketing, distributing, and
3 advertising Non-Drowsy Products throughout the United States. Defendant created and/or
4 authorized the false and misleading advertising and labeling of the Non-Drowsy Products.

5 **JURISDICTION AND VENUE**

6 11. This Court has jurisdiction over this action pursuant to 28 U.S.C. § 1332(d) because
7 there are more than 100 Class members; the aggregate amount in controversy exceeds
8 \$5,000,000.00, exclusive of interest, fees, and costs; and at least one Class member is a citizen of a
9 state different from the Defendant.

10 12. This Court has personal jurisdiction over Defendant because Defendant is
11 headquartered in Washington, regularly conducts business in this District, and has extensive
12 contacts with this forum.

13 13. Venue is proper in this District pursuant to 28 U.S.C. § 1391 because Defendant is
14 headquartered in this District, and Defendant transacts substantial business in this District.

15 **FACTUAL ALLEGATIONS**

16 **A. Defendant Manufactures, Distributes, Markets, and Sells the Non-Drowsy Products**

17 14. Defendant manufactures, distributes, markets, and sells the Non-Drowsy Products.

18 15. Each of the Non-Drowsy Products prominently state on its label that the product is
19 “Non-Drowsy” and some also include the representation that product is intended for “Daytime” use.

20 16. For example, below is an image of the Basic Care Tussin CF Severe’s product label.
21
22
23
24
25
26
27
28



17. The Basic Care Daytime Cold & Flu product label includes the same representations, with the addition of the Daytime representation on its label.



18. The Non-Drowsy Products are also sold in combo packs with NightTime products. For example, below is an image of the Amazon Daytime Severe Cold & Flu combo pack which includes “Daytime” and “Nighttime” formulations.



19. The Nighttime product includes the representation that the product is for “Nighttime Relief” whereas the Daytime product includes “Non-Drowsy” and “Daytime Relief” representations.

20. Both the Daytime and Nighttime products contain DM HBr, the ingredient in the Non-Drowsy Products that causes drowsiness.

21. The “Non-Drowsy” and “Daytime” representations are materially the same across the Non-Drowsy Products.

22. Based on the prominent “Non-Drowsy” and “Daytime” representations included on the front of each product, a reasonable consumer would believe that the products do not cause drowsiness and that drowsiness is not a side effect of the product.

B. Defendant’s False and Misleading Advertising Campaign

23. One of the active ingredients in the Non-Drowsy Products is DM HBr.

24. Drowsiness is a well-documented side effect of DM HBr.

25. For example, the Mayo Clinic and the National Library of Medicine list drowsiness as a side-effect of the ingredient.³

³ *Dextromethorphan: MedlinePlus Drug Information, National Library of Medicine*, <https://medlineplus.gov/druginfo/meds/a682492.html> (last accessed March 23, 2022); *Mayo Clinic, Drugs and Supplements Dextromethorphan (Oral Route)*, <https://www.mayoclinic.org/drugs-supplements/dextromethorphan-oral-route/side-effects/drg->

26. Manufacturers and distributors know that DM HBr causes drowsiness as their safety data sheets (“SDS”) explicitly state that DM HBr causes and may cause drowsiness.

27. According to Pfizer’s safety datasheet for their Robitussin cough medicine. “Common adverse reactions associated with the clinical use of dextromethorphan hydrobromide include, drowsiness, dizziness, and nausea and vomiting.”⁴

28. Santa Cruz Biotechnology Inc lists acute health effects on their SDS following the consumption of DM HBr such as “Drowsiness, dizziness, excitation, mental confusion and gastrointestinal disturbances have been described following dextromethorphan. Administration.”⁵

29. In other words, sedation is a well-known adverse event of this ingredient.⁶

30. In fact, the Federal Aviation Administration prohibits pilots from flying after taking medicines that contain dextromethorphan. The document titled, “What Over-the-Counter (OTC) medications can I take and still be safe to fly” lists DayQuil as a “No Go” product because it contains dextromethorphan.⁷ The Non-Drowsy Products and DayQuil both contain this ingredient. Specifically, the Non-Drowsy Products are compared to DayQuil on the front panel of the product labels.

20068661?p=1 (last accessed March 23, 2022).

10 Dextromethorphan: MedlinePlus Drug Information, National Library of Medicine, <https://medlineplus.gov/druginfo/meds/a682492.html> (last accessed March 23, 2022).

⁴ Pfizer, *Safety Data Sheet*, https://imgcdn.mckesson.com/CumulusWeb/Click_and_learn/SDS_9PFIZ_ROBITUSSIN_DM_SYRP_ADLT_COUGH_CHEST_HONEY_4OZ.pdf (last accessed March 23, 2022).

⁵ Dextromethorphan Hydrobromide, Material Safety Data Sheet, <https://datasheets.scbt.com/sc-204716.pdf> (last accessed March 23, 2022).

⁶ See Martin, E., Narijo, C., Decleves, X., Labat, L., Lambert, C., Lorient, M. A., ... & Pickering, G. (2019). Dextromethorphan analgesia in a human experimental model of hyperalgesia. *Anesthesiology*, 131(2), 356-368; see also Siu, A. and Drachtman, R. (2007), Dextromethorphan: A Review of N-methyl-d-aspartate Receptor Antagonist in the Management of Pain. *CNS Drug Reviews*, 13: 96-106. <https://doi.org/10.1111/j.1527-3458.2007.00006.x> (“DM is used clinically in the form of salt, dextromethorphan hydrobromide...The majority of DM’s adverse effects occur at the level of the CNS. Neurologic toxicity associated with DM includes dystonia, fatigue, drowsiness, and dizziness”).

⁷ Federal Aviation Administration, *What Over-the-Counter (OTC) medications can I take and still be safe to fly* https://www.faa.gov/licenses_certificates/medical_certification/media/OTCMedicationsforPilots.pdf (last accessed March 23, 2022).



31. The Non-Drowsy Products do not disclose anywhere on the packaging that they do or can cause drowsiness, or that drowsiness is a side effect.

32. As such, Defendant's advertising campaign is false and misleading.

33. The Food and Drug Administration ("FDA") prohibits labeling drugs with "false or misleading" statements. 21 C.F.R. § 201.6. It is misleading to label a product "Non-Drowsy" when it does cause drowsiness, or if drowsiness is a known side effect of one of its active ingredients.

34. While the Federal Regulations relating to the labelling of antitussive drug products do not require products with DM HBr to include an affirmative "drowsiness" warning, *see generally*, 21 C.F.R. § 341.74, Defendant could have simply omitted the false and misleading "Non-Drowsy" representations from its product labels.

35. Other drug makers do not falsely claim that products that include DM HBr are "non-drowsy." For example, Coricidin is a cold symptom relief product for people with high blood pressure. Coricidin is manufactured, sold, and advertised by Bayer. This product contains DM HBr and omits false representations by not labeling the product as "Non-Drowsy."



36. Or, if Defendant wanted to differentiate its Daytime products from its Nighttime products, it could have indicated on the product label that the Daytime products would cause *less* drowsiness than the Nighttime products. For example, the below Dramamine product is advertised as a “less drowsy” formula.



37. Defendant intended that consumers would rely on the “Non-Drowsy” and “Daytime” labeling so that consumers would purchase more products, pay a price premium, and buy them as alternatives to its Nighttime products. The product labels do not warn consumers that the products cause drowsiness, may cause drowsiness, or you may get drowsy from the usage of such products thereby creating an unreasonable risk of harm.

C. Consumers Have Been Harmed By Defendant’s False Representations

38. Defendant knew, or should have known, that Defendant’s “Non-Drowsy Products” are misbranded because they contain DM HBr which causes drowsiness in consumers.

39. Defendant knew, or should have known that products misrepresented material facts concerning the “Non-Drowsy” and “Daytime” representations when in fact the products contained an ingredient that causes drowsiness.

40. Defendant knew, or should have known the representations and statements through its labeling prescribes dangerous uses.

41. Plaintiffs would not have purchased the Non-Drowsy Products, or would have paid less for them, had the Non-Drowsy Products been truthfully and accurately labeled.

CLASS ACTION ALLEGATIONS

42. Plaintiffs bring this action pursuant to Rule 23(a), (b)(2), and (b)(3) of the Federal Rules of Civil Procedure, individually and on behalf of the following Classes:

All persons who purchased one or more of Defendant’s Non-Drowsy Products in the United States for personal/household use within any applicable limitations period (the “Nationwide Class”).

43. Plaintiff Fitzl brings this action individually and on behalf of the following Wisconsin subclass:

All persons who purchased one or more of Defendant’s Non-Drowsy Products in the state of Wisconsin for personal/household use within any applicable limitations (the “Wisconsin Subclass”).

44. Plaintiff Horton brings this action individually and on behalf of the following Ohio subclass:

All persons who purchased one or more of Defendant’s Non-Drowsy Products in the state of Ohio for personal/household use within any applicable limitations (the “Ohio Subclass”).

1 45. Excluded from the Class and Subclass are: (1) any Judge or Magistrate presiding
2 over this action and any members of their families; (2) Defendant, Defendant's subsidiaries,
3 parents, successors, predecessors, and any entities in which Defendant or its parents and any entities
4 in which Defendant has a controlling interest and its current or former employees, officers, and
5 directors; and (3) individuals who allege personal bodily injury resulting from the use of Affected
6 Products.

7 46. Numerosity (Rule 23(a)(1)): The exact number of members of the Class is unknown
8 and currently unavailable to Plaintiffs, but joinder of individual members herein is impractical. The
9 Class is likely comprised of thousands of consumers. The precise number of Class members, and
10 their addresses, is unknown to Plaintiffs at this time, but can be ascertained from Defendant's
11 records and/or retailer records. The members of the Class may be notified of the pendency of this
12 action by mail or email, Internet postings and/or publications, and supplemented (if deemed
13 necessary or appropriate by the Court) by published notice.

14 47. Predominant Common Questions (Rule 23(a)(2) and (b)(3)): The Class's claims
15 present common questions of law and fact, and those questions predominate over any questions that
16 may affect individual Class members. The common and legal questions include, but are not limited
17 to, the following:

- 18 a. Whether the Non-Drowsy Products cause drowsiness;
19 b. Whether Defendant's labelling of the Non-Drowsy Products as "Non-
20 Drowsy" and "Daytime" is false, misleading, and/or deceptive;
21 c. Whether Defendant violated the state consumer protection statutes alleged
22 herein;
23 d. Whether Defendant breached its express warranties;
24 e. Whether Defendant was unjustly enriched; and
25 f. The nature of relief, including damages and equitable relief, to which
26 Plaintiffs and members of the Class are entitled.

27 48. Typicality of Claims (Rule 23(a)(3)): Plaintiffs' claims are typical of the claims of
28

1 the Class because Plaintiffs, like all other Class Members, purchased the Non-Drowsy Products,
2 suffered damages as a result of that purchase, and seek the same relief as the proposed Class
3 Members.

4 49. Adequacy of Representation (Rule 23(a)(4)): Plaintiffs adequately represent the
5 Class because their interests do not conflict with the interests of the members of the Class, and they
6 have retained counsel competent and experienced in complex class action and consumer litigation.
7 Plaintiffs and their counsel will fairly and adequately protect the interest of the members of the
8 Class.

9 50. Superiority (Rule 23(b)(3)): A class action is superior to other available means of
10 adjudication for this controversy. It would be impracticable for members of the Class to individually
11 litigate their own claims against Defendant because the damages suffered by Plaintiffs and the
12 members of the Class are relatively small compared to the cost of individually litigating their
13 claims. Individual litigation would create the potential for inconsistent judgments and delay and
14 expenses to the court system. A class action provides an efficient means for adjudication with fewer
15 management difficulties and comprehensive supervision by a single court.

16 51. Declaratory Relief (Fed. R. Civ. P. 23(b)(1) and (2)): In the alternative, this action
17 may properly be maintained as a class action because the prosecution of separate actions by
18 individual members of the Class would create a risk of inconsistent or varying adjudication with
19 respect to individual Class members, which would establish incompatible standards of conduct for
20 the Defendant; or the prosecution of separate actions by individual Class members would create a
21 risk of adjudications with respect to individual members of the Class which would, as a practical
22 matter, be dispositive of the interests of other members of the Class not parties to the adjudications,
23 or substantially impair or impede their ability to protect their interests; or Defendant has acted or
24 refused to act on grounds generally applicable to the Class, thereby making appropriate final
25 injunctive or corresponding declaratory relief with respect to the Class as a whole.

26 **CAUSES OF ACTION**

27 **COUNT I**

28 **BREACH OF EXPRESS WARRANTY**

(on behalf of Plaintiffs and the Nationwide Class (or alternatively, the Wisconsin and Ohio

Subclasses))

52. Plaintiffs hereby incorporate all other paragraphs of this Complaint and restate them as if fully set forth herein.

53. Defendant marketed and sold its Non-Drowsy Products in the stream of commerce with the intent that its Non-Drowsy Products would be purchased by Plaintiffs and the Classes.

54. In connection with the sale of the Non-Drowsy Products, Defendant, as the designer, manufacturer, marketer, distributor, and/or seller issued written warranties by representing that the Non-Drowsy Products were “Non-Drowsy” and were “Daytime” products. These were affirmations of fact about the products (i.e., a description of the effects) and a promise relating to the goods.

55. In fact, the Non-Drowsy Products do not conform to the above referenced representations because, as alleged in detail above, they cause drowsiness. Thus, the warranty was breached.

56. As a direct and proximate cause of Defendant’s breach of express warranty, Plaintiffs and the Class members have been injured and harmed because they would not have purchased the products had they known that the Non-Drowsy Products cause drowsiness; or (2) they overpaid for the Non-Drowsy Products because they are sold at a premium due to the warranties.

57. On April 13, 2022, prior to filing this action, Defendant was served with a pre-suit notice letter pursuant to U.C.C. § 2-607.

COUNT II

VIOLATION OF THE WISCONSIN FRAUDULENT REPRESENTATIONS LAW

Wis. Stat. Ann. § 100.18, *et seq.*

(on behalf of Plaintiff Fitzl and the Wisconsin Subclass)

57. Plaintiffs incorporate by reference and re-allege each and every allegation set forth above as though fully set forth herein.

58. Plaintiff Fitzl bring this cause of action on behalf of herself and members of the Wisconsin Subclass.

59. The WDTA, (Wis. Stat. Ann. § 100.18, *et seq.*) makes it unlawful for a defendant, with intent to induce an obligation, to make a representation to the public, where the representation

1 was untrue, deceptive, or misleading, and where the representation caused a pecuniary loss. *See*
2 *Chris Hinrichs & Autovation Ltd. v. Dow Chem. Co.*, 2020 WI 2, at *P85 (2020); *K&S Tool & Die*
3 *Corp. v. Perfection Mach. Sales, Inc.*, 2007 WI 70, at *P19 (2007).

4 60. Defendant made representations to the public by offering its Non-Drowsy Products
5 through its various retail streams, including claims, through picture or otherwise, that the products
6 were “Non-Drowsy” and meant for “Daytime” use.

7 61. Defendant’s representations about the “Non-Drowsy” and “Daytime” characteristics
8 of its products were untrue, deceptive, or misleading as the products contained an ingredient which
9 is known to cause drowsiness.

10 62. Defendant’s representations were likely to deceive, and did deceive, Plaintiff Fitzl
11 and reasonable consumers.

12 63. Defendant knew or should have known, through the exercise of reasonable care that
13 the statements were untrue, deceptive, and misleading.

14 64. Defendant’s misrepresentations were intended to induce reliance, and Plaintiff Fitzl
15 saw, read, and reasonably relied on them when purchasing Non-Drowsy Products. Defendant’s
16 misrepresentations were a substantial factor in Plaintiff Fitzl’s purchase decisions.

17 65. In addition, reliance can be inferred because Defendant’s misrepresentations were
18 material, *i.e.*, a reasonable consumer would consider them important in deciding whether to buy the
19 Non-Drowsy Products.

20 66. Defendant’s misrepresentations were a substantial factor and proximate cause in
21 causing damages and losses to Plaintiff Fitzl.

22 67. As a direct and proximate result of these acts, consumers have been and are being
23 harmed. Plaintiff Fitzl and members of the Wisconsin Subclass have suffered injury and actual out-
24 of pocket losses because: (a) Plaintiff Fitzl and members of the Wisconsin Subclass would not have
25 purchased the Non-Drowsy Product if they had known the true facts regarding the products; (b)
26 Plaintiff Fitzl and members of the Wisconsin Subclass paid a price premium due to the
27 misrepresentations about the product; and (c) the Non-Drowsy did not have the promised quality,
28 effectiveness, or value.

68. As a direct and proximate result of Defendant's deceptive acts and practices, Plaintiff Fitzl and Wisconsin Subclass members have been damaged as alleged herein, and are entitled to recover actual damages to the extent permitted by law, including class action rules, in an amount to be proven at trial.

69. In addition, Plaintiff Fitzl and Wisconsin Subclass members seek equitable and injunctive relief against Defendant on terms that the Court considers reasonable, and reasonable attorneys' fees and costs.

COUNT III

VIOLATION OF THE OHIO DECEPTIVE TRADE PRACTICES ACT (OHIO REV. CODE § 4165.01, *ET SEQ.*)

(on behalf of Plaintiff Horton and the Ohio Subclass)

70. Plaintiffs incorporate by reference and re-allege each and every allegation set forth above as though fully set forth herein.

71. Plaintiff Horton bring this cause of action on behalf of herself and members of the Ohio Subclass.

72. Defendant, Plaintiff, and absent Ohio Subclass members are each a "person," as defined by Ohio Rev. Code § 4165.01(D).

73. Defendant advertised, offered, or sold goods or services in Ohio and engaged in trade or commerce directly or indirectly affecting the people of Ohio.

74. Defendant engaged in deceptive trade practices in the course of its business and vocation, in violation of Ohio Rev. Code § 4165.02, including: representing that its goods and services have characteristics, uses, benefits, or qualities that they do not have, in violation of Ohio Rev. Code § 4165.02(A)(7); representing that its goods and services are of a particular standard or quality when they are of another, in violation of Ohio Rev. Code § 4165.02(A)(9); and advertising its goods and services with intent not to sell them as advertise, in violation of Ohio Rev. Code § 4165.02(A)(11).

75. By representing on its product packaging that its Non-Drowsy Products are "Non-Drowsy" and for "Daytime" use, whereas in reality the Non-Drowsy Products contain an ingredient

1 known to cause drowsiness, Defendant knowingly and intentionally made material
2 misrepresentations of material facts, in violation of the Ohio Deceptive Trade Practices Act.

3 76. Defendant's representations were material because they were likely to deceive
4 reasonable consumers.

5 77. Defendant intended to mislead Plaintiff Horton and Ohio Subclass members and
6 induce them to rely on its misrepresentations and omissions.

7 78. Defendant acted intentionally, knowingly, and maliciously to violate Ohio's
8 Deceptive Trade Practices Act, and recklessly disregarded Plaintiff Horton's and Ohio Subclass
9 members' rights.

10 79. As a direct and proximate result of Defendant's deceptive acts and practices, Plaintiff
11 Horton and absent Ohio Subclass members have suffered and will continue to suffer injury,
12 ascertainable losses of money or property, and monetary and non-monetary damages.

13 80. Plaintiff Horton and members of the Ohio Subclass are entitled to damages or other
14 appropriate legal or equitable relief, pursuant to the OH DTPA, as set forth above.

15 **COUNT IV**

16 **UNJUST ENRICHMENT**
17 **(on behalf of the Plaintiffs and the Nationwide Class)**

18 81. Plaintiffs hereby incorporate all other paragraphs of this Complaint and restate them
19 as if fully set forth herein.

20 82. Plaintiffs and Class members conferred benefits upon Defendant. Plaintiffs and Class
21 members paid money for Defendant's Non-Drowsy Products that they would not have paid, had
22 they known that the products cause drowsiness.

23 83. Defendant has unjustly retained the benefits conferred upon by Plaintiffs and Class
24 members.

25 84. Defendant retained those benefits under circumstances that make it inequitable for
26 Defendant to retain such benefits. Specifically, Defendant retained those benefits even though
27 Defendant's Non-Drowsy Products cause drowsiness. If Plaintiffs and Class members had known
28 the true nature of Defendant's Non-Drowsy Products, they would not have purchased the products.

1 Plaintiffs and Class members are therefore entitled to disgorgement and/or restitution as prayed for
2 hereunder.

3 85. Because Defendant's retention of the non-gratuitous benefits conferred on it by
4 Plaintiffs and members of the Class is unjust and inequitable, Defendant must pay restitution to
5 Plaintiffs and members of the Class for its unjust enrichment, as ordered by the Court.

6 **COUNT V**

7 **NEGLIGENT MISREPRESENTATION**
8 **(on behalf of the Plaintiffs and the Nationwide Class or, alternatively, the Wisconsin and Ohio**
9 **Subclasses)**

10 86. Plaintiffs hereby incorporate all other paragraphs of this Complaint and restate them
11 as if fully set forth herein.

12 87. Plaintiffs bring this claim against Defendant on behalf of themselves and the
13 proposed Class.

14 88. Defendant has made material misrepresentations of fact concerning the nature of,
15 and ingredients in, the Non-Drowsy Products to Plaintiffs and the Class.

16 89. Defendant has and had no reasonable basis for believing that their misrepresentations
17 were true.
18

19 90. Defendant knew, or should have known, that Plaintiffs and the members of the Class
20 would rely on the false representations about the nature of, and ingredients in, the Non-Drowsy
21 Products.

22 91. Defendant's false representations about the ingredients of the Non-Drowsy Products
23 are objectively material to reasonable consumers, and therefore reliance upon such representations
24 may be presumed as a matter of law.
25

26 92. Plaintiffs and members of the Class have read and reasonably relied to their
27 detriment on Defendant's false and misleading representations, which caused them to purchase the
28 Non-Drowsy Products.

1 purchasers of the Non-Drowsy Products.

2 103. As a proximate result of Defendant's intentional misrepresentations, Plaintiffs and
3 the members of the Class suffered an ascertainable loss and are entitled to relief and compensatory
4 and punitive damages, in an amount to be determined at trial.

5 **PRAYER FOR RELIEF**

6 **WHEREFORE**, Plaintiffs, on behalf of themselves and the proposed Classes, pray for relief
7 and judgment against Defendant as follows:

- 8 a. Certifying the Classes pursuant to Rule 23 of the Federal Rules of Civil Procedure,
9 appointing Plaintiffs as representatives of the Class, and designating Plaintiffs' counsel as
10 Class Counsel;
11 b. Awarding Plaintiffs and the Classes compensatory damages, in an amount exceeding
12 \$5,000,000, to be determined by proof;
13 c. Awarding Plaintiffs and the Classes appropriate relief, including but not limited to
14 actual damages;
15 d. For declaratory and equitable relief, including restitution and disgorgement;
16 e. For an order enjoining Defendant from continuing to engage in the wrongful acts and
17 practices alleged herein;
18 f. Awarding Plaintiffs and the Classes the costs of prosecuting this action, including
19 expert witness fees;
20 g. Awarding Plaintiffs and the Classes reasonable attorneys' fees and costs as allowable
21 by law;
22 h. Awarding pre-judgment and post-judgment interest;
23 i. For punitive damages; and
24 j. Granting any other relief as this Court may deem just and proper.
25
26
27
28

JURY TRIAL DEMANDED

Plaintiffs hereby demand a trial by jury of all claims so triable.

Dated: April 22, 2022

Respectfully submitted,

PHILLIPS LAW FIRM

Ralph Glenn Phillips

Ralph Glenn Phillips, WSBA # 14220

Douglas Weinmaster, WSBA #28225

17410 133rd Avenue NE, Suite 301

Woodinville, WA 98072

Telephone: (425) 482-1111

Facsimile: (425) 482-6653

Email: Glenn@Justiceforyou.com

Email: Dweinmaster@justiceforyou.com

Nick Suciu III (*pro hac vice* to be filed)

MILBERG COLEMAN BRYSON

PHILLIPS GROSSMAN PLLC

6905 Telegraph Rd., Suite 115

Bloomfield Hills, MI 48301

Telephone: 313-303-3472

Email: nsuciu@milberg.com

Gary M. Klinger (*pro hac vice* to be filed)

MILBERG COLEMAN BRYSON

PHILLIPS GROSSMAN, PLLC

227 W. Monroe Street, Suite 2100

Chicago, IL 60606

Telephone: 866.252.0878

Email: gklinger@milberg.com

LEVI & KORSINSKY, LLP

Mark S. Reich (*pro hac vice* to be filed)

Courtney E. Maccarone (*pro hac vice* to be filed)

55 Broadway, 10th Floor

New York, NY 10006

Telephone: 212-363-7500

Facsimile: 212-363-7171

Email: mreich@zlk.com

Email: cmaccarone@zlk

Counsel for Plaintiffs